Allarity Therapeutics Inc (ALLR): Doesn't look very promising....

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

News Focus

News Focus

Allarity Therapeutics Inc (ALLR)

Keep Last Read

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	31
Posts	6640
Boards Moderated	0
Alias Born	08/11/2016

Re: Klinsmann post# 151

Monday, 05/15/2023 9:37:01 AM

Monday, May 15, 2023 9:37:01 AM

Doesn't look very promising....

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent ALLR News

Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 12:54:39 PM
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:02:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:22:50 PM
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:00:48 PM
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need • GlobeNewswire Inc. • 02/18/2026 01:15:00 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/12/2026 09:18:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:00:35 PM
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment • GlobeNewswire Inc. • 02/03/2026 01:00:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/29/2026 01:00:18 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:49:37 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:13:58 PM
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders • GlobeNewswire Inc. • 12/31/2025 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 02:21:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 02:16:37 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:20 AM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/03/2025 02:11:40 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:00:59 PM
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2025 08:05:10 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/30/2025 09:17:29 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2025 09:19:46 PM

More ALLR News

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow